China Pharma Holdings, Inc.

China Pharma Holdings, Inc. (CPHI) reported FY2025 results showing meaningful progress in loss reduction and cash generation despite revenue headwinds. Revenue fell 8.5% to $4.1 million from $4.5 million in FY2024, primarily due to lower sales of Candesartan, as highlighted in management's discussion. This product-specific weakness reflects competitive pressures in centralized procurement channels, though new initiatives provided some offset.

Operating and net losses continued to narrow, with operating loss improving 29.4% to -$3.2 million and net loss declining 32.7% to -$3.2 million. As management explains, the decrease in net loss stemmed mainly from expenses declining more than revenue, reflecting disciplined cost control across selling, general, and administrative functions amid softer demand. Diluted EPS worsened to -$0.74 from -$0.27 due to share count dynamics, but bottom-line improvement signals better expense leverage.

Looking ahead, reliance on a few distributors for major revenue persists as a risk, and CEO funding continuity remains uncertain. Yet the cost structure reset from depreciated assets and positive cash generation provide a foundation for stability as CMO ramps.